Market research
FAD2.F Advaxis, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2.25
- Dividend yield
- 0.0%
- Beta
- 2.07
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 14M
- P/E ratio
- Not available
- Analyst target
- 2.25
- Dividend yield
- 0.0%
- Beta
- 2.07
About
About Advaxis, Inc
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the FAD2.F discussion.
5 years, 5 months ago
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 26.9.
Based on the above factors, Advaxis, Inc gets an overall score of 1/5.